

An FDA-approved assay for monitoring **glycemic control** in diabetic patients.

Clinical Application

- GlycoMark is an assay reflective of postprandial glucose (PPG) spikes¹
- PPG may affect patients who appear in control and can lead to cardiovascular complications²
- GlycoMark is a simple sugar called 1,5 AG that targets glycemic response above the renal threshold
 - Recommended as an adjunct to routine A_{1c} testing¹
- GlycoMark is the only serum test available to monitor the effectiveness of therapeutics targeting PPG^{1,2}
- GlycoMark is a more rapid and sensitive response to hyperglycemia than A_{1c}^{1,2}
- Depicts recent two-week status rather than two-month average³


Scientific Expertise

- Industry-leading Endocrine Sciences laboratory with 30+ year history
- Extensive diabetes test menu including diabetes antibody profiles
- Assay methods developed, validated, and maintained on-site by PhD-level scientists
- Complete normative data from premature infants to elderly adults
- PhD and MD consultation available


Superior Service

- Comprehensive services for the endocrinology specialist
- Extensive network of managed care health plans
- Flexible connectivity options for test ordering and result reporting
- Patient service centers located nationwide
- Courier and logistics services
- Local sales representation

Utilize GlycoMark to target and monitor specific therapeutics for PPG



Utilizing GlycoMark® to Reach Glycemic Goals⁴⁻⁷



Test Name	GlycoMark®			Comprehensive GlycoMark® and A _{1C} Profile		
Test Numbers	500115 (LabCorp Account) 500609 (Esoterix Account)			502226 (LabCorp Account) 501881 (Esoterix Account)		
Method	Enzymatic, colorimetric assay			Enzymatic, colorimetric and HPLC		
Specimen Requirement	1 mL serum (red-top or gel-barrier tube) or plasma (lavender-top EDTA). Room temperature (for same-day shipping) or refrigerate. Minimum: 0.75 mL			5 mL whole blood (lavender-top) AND 1mL serum (red-top or gel-barrier tube)		
CPT	84378			84378; 83036		
Assay Schedule/ Result Turnaround	Monday-Saturday /1 day			Monday-Saturday /1 day		
Reference Ranges	1,5-AG	Mean (SD)	Reference interval	1,5-AG	Mean (SD)	Reference interval
		µg/mL	µg/mL			
	Males	22.5 (5.8)	10.7-32.0	Males	22.5 (5.8) µg/mL	10.7-32.0 µg/mL
	Females	17.7 (6.2)	6.8-29.3	Females	17.7 (6.2) µg/mL	6.8-29.3 µg/mL
			Hemoglobin A_{1C}	4.2 - 5.9%		

General Guidelines for Applying GlycoMark in Diabetes Assessment⁴⁻⁷

GlycoMark (µg/mL)	Assessment of Diabetes
>10	Well-controlled
5-10	Moderately Controlled
2-5	Poor Control
<2	Very Poor Control

Note: GlycoMark may be used monthly.

References

- Dungan KM, Buse JB, Largay J, et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. *Diabetes Care*. 2006;29(6):1214-1219.
- Dworacka M, Winiarska H, Szymanska M, Kuczynski S, Szczawinska K, Wierusz-Whsocka B. 1,5-anhydro-D-glucitol: a novel marker of glucose excursions. *Int J Clin Pract* (suppl). 2002;129:40-44.
- McGill JB, Cole TG, Nowatzke W, et al. Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia. *Diabetes Care*. 2004;27(8):1859-1865.
- Utilizing GlycoMark to Reach Glycemic Goals. Available at http://www.glycomark.com/healthcare/diabetes_mgmt.asp. Accessed: January 8, 2009. Adapted with permission.
- Matsuura K, Mori Y, Tajima N. Determination of an optimal 1,5-AG value for detecting postprandial hyperglycemia by using ROC analyses. American Diabetes Association 68th Annual Scientific Sessions, San Francisco, Calif, 2008. Abstract 1979-PO.
- Dungan K, Buse J, Button E, Wittlin S. Serum 1,5 Anhydroglucitol (1,5-AG) as an adjunct to A1c testing- reflecting both postprandial hyperglycemia and short-term glycemic control. American Diabetes Association, 2006. Abstract 385-P.
- Buse JB, Dungan K, Wittlin SD, Button EA, Kato S, Tanabe T. The 1,5-Anhydroglucitol assay and A1c/1,5-AG assay combination for measuring blood glucose excursions in general postprandial hyperglycemia in diabetic patients. World Patent 2006/116083. Available at <http://www.wipo.int/pctdb/en/wo.jsp?WO=2006%2F116083&IA=WO2006%2F116083&DISPLAY=DESC>. Accessed: March 5, 2009.

ESOTERIX^U
Laboratory Services

www.esoterix.com

LabCorp
Laboratory Corporation of America

www.LabCorp.com

Esoterix is a wholly owned subsidiary of Laboratory Corporation of America® Holdings. Its Endocrine Sciences laboratory operates as a LabCorp Center of Excellence for specialized endocrinology. Endocrine Sciences' testing can be accessed directly from Esoterix or through LabCorp and any of its regional facilities.